GEN Exclusives

More »

GEN News Highlights

More »
Jul 27, 2009

RXi Gains Rights to Advirna’s RNAi Delivery Platform

  • RXi Pharmaceuticals exercised its option to acquire an exclusive, worldwide license to Advirna’s RNAi delivery technology. The technologies licensed from Advirna encompass four approaches, focused primarily on self-delivery of RNAi therapeutics.

    Advirna’s technology has been integrated into RXi’s rxRNA™ platform to generate so-called self-delivering rxRNAs (sd-rxRNAs), which the company maintains require no separate delivery vehicle such as liposomes, complexes, or nanoparticles. Additional advantages of the new sd-rxRNAs are reported to include their spontaneous cellular uptake, patient-friendly (subcutaneous) administration, tissue-targeted biodistribution/reduced renal clearance, and reduced side-effects. 

    “The ability to create self-delivering RNAi therapeutics promises to provide significant competitive advantages in efficacy, toxicity, ease of administration, and manufacturing costs,” states RXi president and CEO, Tod Woolf, Ph.D.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?